Influenza epidemics are responsible for high mortality and morbidity rates in particular among elderly and high risk groups. This review is aimed at assessing the economic value of vaccination in these groups. A search of full economic evaluations of influenza vaccination in comparison with no interventions was performed on PubMed from January 1990 to May 2011. Only economic evaluations dealing with elderly and high risk groups were considered. The quality of selected articles was assessed through Drummond's checklist. Sixteen cost-effectiveness analyses and four cost-benefit analyses were included: overall, the quality of studies was fairly good. The vaccination was demonstrated to be cost-effective or cost-saving in almost all studies, independently by the perspective and the type of analysis. Influenza vaccination is a worthwhile intervention from the pharmacoeconomic view-point, anyway a standardization of methods should be desirable in order to guarantee the comparability and transferability of results.

De Waure, C., Veneziano, M. A., Cadeddu, C., Capizzi, S., Specchia, M. L., Capri, S., Ricciardi, G., Economic value of influenza vaccination, <<HUMAN VACCINES & IMMUNOTHERAPEUTICS>>, 2012; 8 (1): 119-129. [doi:10.4161/hv.8.1.18420] [http://hdl.handle.net/10807/7885]

Economic value of influenza vaccination

De Waure, Chiara;Veneziano, Maria Assunta;Cadeddu, Chiara;Capizzi, Silvio;Specchia, Maria Lucia;Ricciardi, Gualtiero
2012

Abstract

Influenza epidemics are responsible for high mortality and morbidity rates in particular among elderly and high risk groups. This review is aimed at assessing the economic value of vaccination in these groups. A search of full economic evaluations of influenza vaccination in comparison with no interventions was performed on PubMed from January 1990 to May 2011. Only economic evaluations dealing with elderly and high risk groups were considered. The quality of selected articles was assessed through Drummond's checklist. Sixteen cost-effectiveness analyses and four cost-benefit analyses were included: overall, the quality of studies was fairly good. The vaccination was demonstrated to be cost-effective or cost-saving in almost all studies, independently by the perspective and the type of analysis. Influenza vaccination is a worthwhile intervention from the pharmacoeconomic view-point, anyway a standardization of methods should be desirable in order to guarantee the comparability and transferability of results.
Inglese
De Waure, C., Veneziano, M. A., Cadeddu, C., Capizzi, S., Specchia, M. L., Capri, S., Ricciardi, G., Economic value of influenza vaccination, <<HUMAN VACCINES & IMMUNOTHERAPEUTICS>>, 2012; 8 (1): 119-129. [doi:10.4161/hv.8.1.18420] [http://hdl.handle.net/10807/7885]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/7885
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact